Telix Pharmaceuticals Limited (TLX) Revenue History
Annual and quarterly revenue from 2017 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TLX Revenue Growth
Revenue Breakdown (FY 2018)
TLX's revenue distribution by segment and geography for fiscal year 2018
By Product/Segment
By Geography
TLX Revenue Analysis (2017–2024)
As of May 8, 2026, Telix Pharmaceuticals Limited (TLX) generated trailing twelve-month (TTM) revenue of $1.66 billion, reflecting explosive growth of +213.9% year-over-year. The most recent quarter (Q2 2025) recorded $593.1 million in revenue, down 0.2% sequentially.
Looking at the longer-term picture, TLX's 5-year compound annual growth rate (CAGR) stands at +195.3%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $783.2 million in 2024, representing a new all-time high.
Revenue diversification analysis shows TLX's business is primarily driven by Digital Product Sales (88%), and Digital Product Lease And Maintenance (12%). With over half of revenue concentrated in Digital Product Sales, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including EXEL (+3.3% YoY), RNW (+50.5% YoY), and AGEN (+10.4% YoY), TLX has outperformed the peer group in terms of revenue growth. Compare TLX vs EXEL →
TLX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TLXCurrent | $1.7B | +213.9% | +195.3% | 10.5% | |
 EXEL | $2.3B | +3.3% | +18.6% | 37.6% | |
 RNW | $97.1B | +50.5% | +14.9% | 53.5% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% | |
 LNTH | $1.5B | +0.6% | +35.3% | 20.2% | |
 NVS | $54.8B | +5.3% | +1.9% | 31.2% |
TLX Historical Revenue Data (2017–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $783.2M | +55.8% | $509.7M | 65.1% | $82.1M | 10.5% |
| 2023 | $502.5M | +213.9% | $314.4M | 62.6% | $51.9M | 10.3% |
| 2022 | $160.1M | +2007.6% | $29.3M | 18.3% | $-91,930,000 | -57.4% |
| 2021 | $7.6M | +45.7% | $-29,765,000 | -391.9% | $-81,247,000 | -1069.6% |
| 2020 | $5.2M | +49.6% | $-16,877,000 | -323.7% | $-49,253,000 | -944.8% |
| 2019 | $3.5M | +1685.9% | $-11,875,000 | -340.7% | $-40,256,000 | -1155.1% |
| 2018 | $195K | - | $195K | 100.0% | $-15,684,875 | -8037.7% |
| 2017 | $0 | - | $-3,793 | - | $-6,367,714 | - |
See TLX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TLX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TLX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTLX — Frequently Asked Questions
Quick answers to the most common questions about buying TLX stock.
Is TLX's revenue growth accelerating or slowing?
TLX revenue is accelerating at +213.9% year-over-year, exceeding the 5-year CAGR of +195.3%. TTM revenue reached $1.7B. Growth momentum has increased versus prior periods.
What is TLX's long-term revenue growth rate?
Telix Pharmaceuticals Limited's 5-year revenue CAGR of +195.3% reflects the sustained expansion pattern. Current YoY growth of +213.9% is above this long-term average.
How is TLX's revenue distributed by segment?
TLX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2024 are available for download. Segment mix reveals concentration and diversification trends.